{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:30:50Z","timestamp":1783632650851,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,8]],"date-time":"2020-03-08T00:00:00Z","timestamp":1583625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,8]],"date-time":"2020-03-08T00:00:00Z","timestamp":1583625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12020-020-02245-0","type":"journal-article","created":{"date-parts":[[2020,3,8]],"date-time":"2020-03-08T12:02:25Z","timestamp":1583668945000},"page":"133-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Locally unresectable differentiated thyroid cancer: outcomes and perspectives"],"prefix":"10.1007","volume":"69","author":[{"name":"with the support of the TUTHYREF network","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3640-1204","authenticated-orcid":false,"given":"L.","family":"Lamartina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Godbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Al Ghuzlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hadoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berdelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Terroir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schlumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Leboulleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,8]]},"reference":[{"issue":"4","key":"2245_CR1","doi-asserted-by":"crossref","first-page":"R209","DOI":"10.1530\/ERC-17-0542","volume":"25","author":"A Berdelou","year":"2018","unstructured":"A. Berdelou, L. Lamartina, M. Klain, S. Leboulleux, M. Schlumberger, Treatment of refractory thyroid cancer. Endocr. Relat. Cancer 25(4), R209\u2013r23 (2018)","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"2245_CR2","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli et al., Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892\u20132899 (2006)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2245_CR3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1634\/theoncologist.2015-0107","volume":"21","author":"J Wassermann","year":"2016","unstructured":"J. Wassermann, M.O. Bernier, J.P. Spano, C. Lepoutre-Lussey, C. Buffet, J.M. Simon et al., Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas. Oncologist 21, 50\u201358 (2016)","journal-title":"Oncologist"},{"issue":"5","key":"2245_CR4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","volume":"2","author":"M Schlumberger","year":"2014","unstructured":"M. Schlumberger, M. Brose, R. Elisei, S. Leboulleux, M. Luster, F. Pitoia et al., Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2(5), 356\u2013358 (2014)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"2245_CR5","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1210\/jcem.86.4.7407","volume":"86","author":"EL Mazzaferri","year":"2001","unstructured":"E.L. Mazzaferri, R.T. Kloos, Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 86(4), 1447\u20131463 (2001)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"23","key":"2245_CR6","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","volume":"27","author":"MJ Schlumberger","year":"2009","unstructured":"M.J. Schlumberger, R. Elisei, L. Bastholt, L.J. Wirth, R.G. Martins, L.D. Locati et al., Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J. Clin. Oncol. 27(23), 3794\u20133801 (2009)","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"2245_CR7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","volume":"13","author":"S Leboulleux","year":"2012","unstructured":"S. Leboulleux, L. Bastholt, T. Krause, C. de la Fouchardiere, J. Tennvall, A. Awada et al., Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 13(9), 897\u2013905 (2012)","journal-title":"Lancet Oncol."},{"issue":"9940","key":"2245_CR8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt et al., Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 384(9940), 319\u2013328 (2014)","journal-title":"Lancet."},{"issue":"7","key":"2245_CR9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei et al., Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621\u2013630 (2015)","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"2245_CR10","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","volume":"17","author":"MS Brose","year":"2016","unstructured":"M.S. Brose, M.E. Cabanillas, E.E. Cohen, L.J. Wirth, T. Riehl, H. Yue et al., Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 17(9), 1272\u20131282 (2016)","journal-title":"Lancet Oncol."},{"issue":"7","key":"2245_CR11","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1210\/jc.2015-4391","volume":"101","author":"L Lamartina","year":"2016","unstructured":"L. Lamartina, S. Ippolito, M. Danis, F. Bidault, I. Borget, A. Berdelou, et al., Antiangiogenic tyrosine kinase inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer. J. Clin. Endocrinol. Metab. 101(7), 2733\u20132741 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2245_CR12","doi-asserted-by":"publisher","unstructured":"D.M. Hartl, J. Guerlain, I. Bresuskin, E. Baudin, L. Lamartina, J. Hadoux, et al., Surgery in the context of kinase inhibitor therapy for locally invasive thyroid cancer. Eur. J. Surg. Oncol. 2019. https:\/\/doi.org\/10.1016\/j.ejso.2019.09.184","DOI":"10.1016\/j.ejso.2019.09.184"},{"issue":"6","key":"2245_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, E.T. McFadden et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5(6), 649\u2013655 (1982)","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"2245_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228\u2013247 (2009)","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"2245_CR15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1097\/00005537-199809000-00029","volume":"108","author":"SW Bayles","year":"1998","unstructured":"S.W. Bayles, T.T. Kingdom, G.W. Carlson, Management of thyroid carcinoma invading the aerodigestive tract. Laryngoscope 108(9), 1402\u20131407 (1998)","journal-title":"Laryngoscope"},{"issue":"8","key":"2245_CR16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00268-002-6612-1","volume":"26","author":"ID Hay","year":"2002","unstructured":"I.D. Hay, G.B. Thompson, C.S. Grant, E.J. Bergstralh, C.E. Dvorak, C.A. Gorman et al., Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940\u20131999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J. Surg. 26(8), 879\u2013885 (2002)","journal-title":"World J. Surg."},{"issue":"4","key":"2245_CR17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/lary.20800","volume":"120","author":"J Honings","year":"2010","unstructured":"J. Honings, A.E. Stephen, H.A. Marres, H.A. Gaissert, The management of thyroid carcinoma invading the larynx or trachea. Laryngoscope 120(4), 682\u2013689 (2010)","journal-title":"Laryngoscope"},{"issue":"3","key":"2245_CR18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1067\/mhn.2001.113141","volume":"124","author":"S Ortiz","year":"2001","unstructured":"S. Ortiz, J.M. Rodriguez, T. Soria, D. Perez-Flores, A. Pinero, J. Moreno et al., Extrathyroid spread in papillary carcinoma of the thyroid: clinicopathological and prognostic study. Otolaryngol. Head. Neck Surg. 124(3), 261\u2013265 (2001)","journal-title":"Otolaryngol. Head. Neck Surg."},{"issue":"5","key":"2245_CR19","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.otohns.2005.11.040","volume":"134","author":"K Segal","year":"2006","unstructured":"K. Segal, T. Shpitzer, A. Hazan, G. Bachar, G. Marshak, A. Popovtzer, Invasive well-differentiated thyroid carcinoma: effect of treatment modalities on outcome. Otolaryngol. Head. Neck Surg. 134(5), 819\u2013822 (2006)","journal-title":"Otolaryngol. Head. Neck Surg."},{"issue":"2","key":"2245_CR20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/hed.2880160211","volume":"16","author":"TV McCaffrey","year":"1994","unstructured":"T.V. McCaffrey, E.J. Bergstralh, I.D. Hay, Locally invasive papillary thyroid carcinoma: 1940\u20131990. Head. Neck. 16(2), 165\u2013172 (1994)","journal-title":"Head. Neck."},{"issue":"8","key":"2245_CR21","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0046-8177(93)90136-5","volume":"24","author":"DH Shin","year":"1993","unstructured":"D.H. Shin, E.J. Mark, H.C. Suen, H.C. Grillo, Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extension to the trachea: a clinicopathologic study based on 22 patients who underwent thyroidectomy and airway resection. Hum. Pathol. 24(8), 866\u2013870 (1993)","journal-title":"Hum. Pathol."},{"issue":"5","key":"2245_CR22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s00268-005-0270-z","volume":"30","author":"Y Ito","year":"2006","unstructured":"Y. Ito, C. Tomoda, T. Uruno, Y. Takamura, A. Miya, K. Kobayashi et al., Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J. Surg. 30(5), 780\u2013786 (2006)","journal-title":"World J. Surg."},{"issue":"1","key":"2245_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.MLG.0000200428.26975.86","volume":"116","author":"JC McCaffrey","year":"2006","unstructured":"J.C. McCaffrey, Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology. Laryngoscope 116(1), 1\u201311 (2006)","journal-title":"Laryngoscope"},{"issue":"1","key":"2245_CR24","first-page":"1","volume":"26","author":"BR Haugen","year":"2015","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al., American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016 26(1), 1\u2013133 (2015)","journal-title":"Thyroid 2016"},{"issue":"6","key":"2245_CR25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1530\/eje.1.02158","volume":"154","author":"F Pacini","year":"2006","unstructured":"F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, W. Wiersinga, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154(6), 787\u2013803 (2006)","journal-title":"Eur. J. Endocrinol."},{"issue":"Suppl 1","key":"2245_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12515","volume":"81","author":"P Perros","year":"2014","unstructured":"P. Perros, K. Boelaert, S. Colley, C. Evans, R.M. Evans, G. Gerrard Ba et al., Guidelines for the management of thyroid cancer. Clin. Endocrinol. 81(Suppl 1), 1\u2013122 (2014)","journal-title":"Clin. Endocrinol."},{"issue":"7","key":"2245_CR27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hed.23406","volume":"36","author":"DM Hartl","year":"2014","unstructured":"D.M. Hartl, S. Zago, S. Leboulleux, H. Mirghani, D. Deandreis, E. Baudin et al., Resection margins and prognosis in locally invasive thyroid cancer. Head. Neck. 36(7), 1034\u20131038 (2014)","journal-title":"Head. Neck."},{"issue":"9","key":"2245_CR28","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1089\/thy.2016.0064","volume":"26","author":"IJ Nixon","year":"2016","unstructured":"I.J. Nixon, R. Simo, K. Newbold, A. Rinaldo, C. Suarez, L.P. Kowalski et al., Management of invasive differentiated thyroid cancer. Thyroid 26(9), 1156\u20131166 (2016)","journal-title":"Thyroid"},{"issue":"10","key":"2245_CR29","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hed.23619","volume":"36","author":"ML Shindo","year":"2014","unstructured":"M.L. Shindo, S.M. Caruana, E. Kandil, J.C. McCaffrey, L.A. Orloff, J.R. Porterfield et al., Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement. Head. Neck. 36(10), 1379\u20131390 (2014)","journal-title":"Head. Neck."},{"issue":"1","key":"2245_CR30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<172::AID-CNCR28>3.0.CO;2-1","volume":"77","author":"J Farahati","year":"1996","unstructured":"J. Farahati, C. Reiners, M. Stuschke, S.P. Muller, G. Stuben, W. Sauerwein et al., Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 77(1), 172\u2013180 (1996)","journal-title":"Cancer"},{"issue":"9 Suppl","key":"2245_CR31","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/1097-0142(19850501)55:9+<2062::AID-CNCR2820551406>3.0.CO;2-O","volume":"55","author":"M Tubiana","year":"1985","unstructured":"M. Tubiana, E. Haddad, M. Schlumberger, C. Hill, P. Rougier, D. Sarrazin, External radiotherapy in thyroid cancers. Cancer 55(9 Suppl), 2062\u20132071 (1985)","journal-title":"Cancer"},{"key":"2245_CR32","first-page":"183461","volume":"2010","author":"MA Sia","year":"2010","unstructured":"M.A. Sia, R.W. Tsang, T. Panzarella, J.D. Brierley, Differentiated thyroid cancer with extrathyroidal extension: prognosis and the role of external beam radiotherapy. J. Thyroid Res. 2010, 183461 (2010)","journal-title":"J. Thyroid Res."},{"issue":"4","key":"2245_CR33","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1677\/erc.1.01320","volume":"13","author":"SM Chow","year":"2006","unstructured":"S.M. Chow, S. Yau, C.K. Kwan, P.C. Poon, S.C. Law, Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr. Relat. Cancer 13(4), 1159\u20131172 (2006)","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"2245_CR34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jso.23656","volume":"110","author":"PB Romesser","year":"2014","unstructured":"P.B. Romesser, E.J. Sherman, A.R. Shaha, M. Lian, R.J. Wong, M. Sabra et al., External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. J. Surg. Oncol. 110(4), 375\u2013382 (2014)","journal-title":"J. Surg. Oncol."},{"issue":"4","key":"2245_CR35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ijrobp.2008.09.023","volume":"74","author":"DL Schwartz","year":"2009","unstructured":"D.L. Schwartz, M.J. Lobo, K.K. Ang, W.H. Morrison, D.I. Rosenthal, A. Ahamad et al., Post-operative external beam radiotherapy for differentiated thyroid cancer\u2014outcomes and morbidity with conformal treatment. Int J. Radiat. Oncol. Biol. Phys. 74(4), 1083\u20131091 (2009)","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"2245_CR36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/archotol.1997.01900050030003","volume":"123","author":"JM Czaja","year":"1997","unstructured":"J.M. Czaja, T.V. McCaffrey, The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma. Arch. Otolaryngol. Head. Neck Surg. 123(5), 484\u2013490 (1997)","journal-title":"Arch. Otolaryngol. Head. Neck Surg."},{"issue":"6","key":"2245_CR37","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.surg.2010.09.011","volume":"148","author":"M Brauckhoff","year":"2010","unstructured":"M. Brauckhoff, A. Machens, P.N. Thanh, K. Lorenz, A. Schmeil, M. Stratmann et al., Impact of extent of resection for thyroid cancer invading the aerodigestive tract on surgical morbidity, local recurrence, and cancer-specific survival. Surgery 148(6), 1257\u20131266 (2010)","journal-title":"Surgery"},{"issue":"6","key":"2245_CR38","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.athoracsur.2007.01.056","volume":"83","author":"HA Gaissert","year":"2007","unstructured":"H.A. Gaissert, J. Honings, H.C. Grillo, D.M. Donahue, J.C. Wain, C.D. Wright et al., Segmental laryngotracheal and tracheal resection for invasive thyroid carcinoma. Ann. Thorac. Surg. 83(6), 1952\u20131959 (2007)","journal-title":"Ann. Thorac. Surg."},{"issue":"2","key":"2245_CR39","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/jc.2005-1534","volume":"91","author":"RJ Robbins","year":"2006","unstructured":"R.J. Robbins, Q. Wan, R.K. Grewal, R. Reibke, M. Gonen, H.W. Strauss et al., Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J. Clin. Endocrinol. Metab. 91(2), 498\u2013505 (2006)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"2245_CR40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1677\/ERC-10-0233","volume":"18","author":"D Deandreis","year":"2011","unstructured":"D. Deandreis, A. Al Ghuzlan, S. Leboulleux, L. Lacroix, J.P. Garsi, M. Talbot et al., Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr. Relat. Cancer 18(1), 159\u2013169 (2011)","journal-title":"Endocr. Relat. Cancer"},{"issue":"5","key":"2245_CR41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/030089169007600513","volume":"76","author":"JP Droz","year":"1990","unstructured":"J.P. Droz, M. Schlumberger, P. Rougier, M. Ghosn, P. Gardet, C. Parmentier, Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76(5), 480\u2013483 (1990)","journal-title":"Tumori"},{"issue":"5","key":"2245_CR42","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1089\/thy.2012.0598","volume":"24","author":"DP Blevins","year":"2014","unstructured":"D.P. Blevins, R. Dadu, M. Hu, C. Baik, D. Balachandran, W. Ross et al., Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 24(5), 918\u2013922 (2014)","journal-title":"Thyroid"},{"issue":"4","key":"2245_CR43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1530\/EJE-13-0825","volume":"170","author":"MH Massicotte","year":"2014","unstructured":"M.H. Massicotte, M. Brassard, M. Claude-Desroches, I. Borget, F. Bonichon, A.L. Giraudet et al., Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur. J. Endocrinol. 170(4), 575\u2013582 (2014)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"2245_CR44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/thy.2014.0361","volume":"25","author":"CN Chougnet","year":"2015","unstructured":"C.N. Chougnet, I. Borget, S. Leboulleux, C. de la Fouchardiere, F. Bonichon, L. Criniere et al., Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid 25(4), 386\u2013391 (2015)","journal-title":"Thyroid"},{"issue":"10","key":"2245_CR45","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","volume":"11","author":"KC Bible","year":"2010","unstructured":"K.C. Bible, V.J. Suman, J.R. Molina, R.C. Smallridge, W.J. Maples, M.E. Menefee et al., Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 11(10), 962\u2013972 (2010)","journal-title":"Lancet Oncol."},{"issue":"29","key":"2245_CR46","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1200\/JCO.2017.73.0226","volume":"35","author":"ME Cabanillas","year":"2017","unstructured":"M.E. Cabanillas, J.A. de Souza, S. Geyer, L.J. Wirth, M.E. Menefee, S.V. Liu et al., Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a Multicenter Phase II International Thyroid Oncology Group Trial. J. Clin. Oncol. 35(29), 3315\u20133321 (2017)","journal-title":"J. Clin. Oncol."},{"key":"2245_CR47","doi-asserted-by":"publisher","unstructured":"G. Feng, Y. Luo, Q. Zhang, F. Zeng, J. Xu, J. Zhu et al., Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis. Endocrine 2020. https:\/\/doi.org\/10.1007\/s12020-019-02167-6","DOI":"10.1007\/s12020-019-02167-6"},{"key":"2245_CR48","doi-asserted-by":"publisher","unstructured":"A. Berdelou, I. Borget, Y. Godbert, T. Nguyen, M.E. Garcia, C.N. Chougnet et al., Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 2017. https:\/\/doi.org\/10.1089\/thy.2017.0205","DOI":"10.1089\/thy.2017.0205"},{"key":"2245_CR49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","volume":"118","author":"LD Locati","year":"2019","unstructured":"L.D. Locati, A. Piovesan, C. Durante, M. Bregni, M.G. Castagna, S. Zovato et al. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur. J. Cancer 118, 35\u201340 (2019)","journal-title":"Eur. J. Cancer"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-020-02245-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T20:15:54Z","timestamp":1722543354000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-020-02245-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,8]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["2245"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02245-0","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,8]]},"assertion":[{"value":"10 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.L. is a member of Sanofi Genzyme, EISAI, Loxo and Bayer Advisory Boards; has received research grants from Sanofi Genzyme, Novartis and Bayer. M.S. has received grants from Bayer, Eisai, Sanofi Genzyme and Exelixis-IPSEN; the other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}